Two Decades of Evolving ASCO Clinical Trial Trends
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025) [] Overheu #ASCO26 Abstract # 11024, Poster Bd # 7 https://t.co/JYI0LY7FbU #ClinicalTrials #ctsm @ASCO
WGS Uncovers Clinically Relevant Findings Missed in MDS
Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS] - @AlexBataller etal @garciamanero @UTMDAnderson @TempusAI #ASCO26 abst 6570 Pst 363 https://t.co/t7aNW89eRL #MDSsm #leusm #cagenome
AQUARIUS Registry Uncovers Biomarkers in Blood Cancers
AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for Pts w/ hematologic malignancies - @mtmdphd et al. @TempusAI & IFLI - Instit Follicular Lymphoma Innovation #ASCO26 abstr TPS7105, Poster 599a https://t.co/70G0v1P968 #NCT07154823 #lymsm #cagenome
AI Monitors Oncologist Chatter at ASCO 2025
AI-powered social media listening of oncologist conversations at ASCO 2025 - Ghosal @brunolarvol @mtmdphd Gramling @Larvol https://t.co/azRDBVYLGK #ASCO26 abstr 9045 Poster Bd # 512 #hemonc #Scicomm #ASCO25 @ASCO
Cancer Patients Evolve Into Expert Co‑Navigators
The Rise of the Expert Patient in Cancer: From Backseat Passenger to Co-navigator [Mar 28, 2022] @AndreaAnampaG @JFreemanDaily et al. @DrSGraff @JCOOP_ASCO https://t.co/PO5mhwZ8hh #COSMonc @COSMOCollab https://t.co/zsKBvUprIE
Funding Global Cancer Research to Cure Every Patient
EVERY CANCER. EVERY PATIENT. EVERYWHERE. @ConquerCancerFd of the American Society of Clinical Oncology (@ASCO) raises funds to support the world's leading researchers who are improving treatments & discovering cures for patients around the world. https://t.co/du6r6gdsgV #ASCO26
Curating Health Hashtags for Better Online Content
Organizing Online Health Content: Developing Hashtag Collections... [6/28/19] - @subatomicdoc @pfanderson @mtmdphd @TheLizArmy @JFreemanDaily @audvin @drdonsdizon @CBlotner_ @DavidCookeMD @womenofteal @stales @fischmd @colleen_young @DrAttai @JCOCCI_ASCO https://t.co/776r7qmxcY https://t.co/usNt21otYF
1q22 Gain Predicts Poor Prognosis in Myeloma
Prognostic significance of acquired 1q22 gain in multiple myeloma [Oct 28, 2021] Hadiyah Y Audil et al. @myelomaMD Am J Hematol https://t.co/qUKCUdnZPH #mmsm #PrecisionMedicine #oncopath HT @EagleMyeloma https://t.co/vd0BVZ6bRq
1q Abnormalities Define Distinct Proteomic Landscape in Myeloma
Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma [Apr 14, 2026] Mangalaparthi et al. @Nature_NPJ https://t.co/XTcJZIGFh6 #mmsm #PrecisionMedicine HT @Myeloma_Doc https://t.co/XyrxJ29elO
US Study Links Telomere Length to Genes, Traits, Geography
Genomic, phenomic and geographic associations of leukocyte telomere length in the United States [Mar 27, 2026] @NakaoTetsushi et al. @NatureGenet https://t.co/3b75zEElAP https://t.co/jWNwYRWkQv
Eltrombopag Proves More Cost-Effective than IVIG Perioperatively
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia [Jan 31, 2022] @ThisIsManraj et al. @BloodJournal https://t.co/2hr1CFmUro #ITP https://t.co/Fz6ZRjJHlk
CM313 Shows Promise as New ITP Therapy
A Novel Anti-CD38 Monoclonal Antibody [CM313] for Treating Immune Thrombocytopenia [Jun 19, 2024] Chen et al. @NEJM https://t.co/o9wf1ogUi4 #NCT05694767 #ITP https://t.co/aSXzpOHOtF
Fostamatinib Shows 79% Response, 54% Complete Remission in ITP
Fostamatinib [Syk inhib] effectiveness and safety for immune thrombocytopenia in clinical practice [August 8, 2024] @tomasjosegonza2 et al. @BloodPortfolio https://t.co/wrctRVBZsJ #ITP 79% RR, 53.6% CR https://t.co/OJfMY0DMah
Rilzabrutinib Shows Safety and Efficacy in Chronic ITP
Safety and efficacy of rilzabrutinib vs placebo in adults with [persistent/chronic] immune thrombocytopenia: the phase 3 LUNA3 study [Jun 12, 2025] Kuter et al. @BloodPortfolio https://t.co/hhnzXg3bqu #NCT04562766 #ITP https://t.co/IkjLnu1kTd
Daratumumab Shows Safety and Efficacy in ITP
Safety and Efficacy of Daratumumab in Immune Thrombocytopenia (#ITP) [Aug 5, 2025] Tsykunova et al. @BloodPortfolio https://t.co/GHyJGG7YSe #NCT04703621 https://t.co/pBgjzTCGQl
Ianalumab Combined with Eltromb
Ianalumab [VAY736] plus Eltrombopag in Immune Thrombocytopenia [Dec 9, 2025] @CukerMd et al. for the VAYHIT2 Investigators @NEJM https://t.co/99urXh8agT #NCT05653219 #ITP https://t.co/qKKhwv4ofR
Stenting Advances Treatment for Post‑thrombotic Syndrome
Stenting for Post-Thrombotic Syndrome — A Step Forward {Editorial} [Apr 13, 2026] Flumignan & Nakano @NEJM https://t.co/w559CHaTON #NCT03250247 #VTE
Endovascular Therapy Shows Promise for Post‑Thrombotic Syndrome
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial [Apr 13, 2026] Vedantham et al. for the C-TRACT [Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy] Trial Investigators @NEJM https://t.co/Ayd4Fa0ARl #NCT03250247 #VTE https://t.co/6iD1NUQdgX
Patient‑Driven Platform Accelerates Multiple Myeloma Research
.@HealthtreeMM Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles & Accelerate Research in Multiple Myeloma [3/10/22] @NSweeneyPhd @AhlstromJenny @FaithEDavies1 @mtmdphd @JCOCCI_ASCO https://t.co/WOwLb9Eozv @myelomacrowd #mmsm https://t.co/6HieAzjSES
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor‑Dex in Myeloma‑Induced Kidney
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/KJfqVVcwEr
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/SKPUQiSaU4
Phase 3 Trial Tests Daratum
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/Hq9VlRCTCI
When to Stop Myeloma Treatment: MRD Insights
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/FIDPrE7QRb
MRD‑negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Approves MRD as Early Endpoint for Myeloma Trials
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/V4wrNgvTrG
Clinicians Show Mixed Adoption of Myeloma MRD Testing
Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/mPtRCjnB9f
Classic Lymphadenopathy Differential Diagnosis Table Highlights Key Features
Lymphadenopathy [2000] Habermann & @DavidSteensma @MayoProceedings https://t.co/56RvIsHEG3 <- a classic esp DDx Table 3 #lymsm #hemeonc https://t.co/PlvEKQVoiG
Unexplained Splenomegaly Study Reveals Preliminary Findings
The Challenge of Unexplained Splenomegalies: Preliminary Data of the French Prospective Multi-Center Splenomegaly Study (SMS) [Nov 29, 2018] Guillaume Denis, MD etal. @BloodJournal 32 (Supplement 1): 4815 #ASH18 https://t.co/N0PeoI1agT #SMUS
Comprehensive Genomic Panel Broadens Oncology Treatment Options
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO https://t.co/tDi3kbxdvX #PrecisionMedicine #hemeonc @TempusAI https://t.co/zgEw8hfFia
Real-World Data Reveal Molecular Profile of Metastatic ILC
Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity [Sep 10, 2025] Davis et al. @CCR_AACR https://t.co/eY0etUfQhQ #bcsm #PrecisionMedicine #camoldx @TempusAI https://t.co/oDkC1Ua6DS
PurIST Classifier Validated for Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/40LqNDQJHo
Iron Deficiency Anemia Often Triggers Thrombocytosis
Thrombocytosis in Iron Deficiency Anemia [Nov 28, 2018] @hemen_712 et al. @BloodJournal https://t.co/BCqznWwhki #hemeonc #anemia
Comprehensive Genomic Landscape of Small Bowel Adenocarcinoma Revealed
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases [May 14, 2024] Aparicio et al. @BrJCancer https://t.co/xfznlhD4fh #sbcsm #cagenome HT @OncoThor
High‑dose Dexamethasone Improves Outcomes in Newly Diagnosed Myeloma
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/GnehXu71Td
Optical Genome Mapping Enhances AML Classification and Treatment
Optical genome mapping [OGM] improves the accuracy of classification, risk stratification, & personalized treatment strategies for Pts w/ acute myeloid leukemia [Jul 17, 2024] @sanamloghavi et al. @AjHematology https://t.co/R5ZLgolhuj #AMLsm #leusm #PrecisionMedicine #oncopath https://t.co/kX7KUJLK0L
Genetics, Traits, and Geography Shape US Leukocyte Telomere Length
Genomic, phenomic and geographic associations of leukocyte telomere length in the United States [Mar 27, 2026] @NakaoTetsushi et al. @NatureGenet https://t.co/3b75zEElAP https://t.co/wIDjfhnrd9
Beyond T(11;14): Expanding Venetoclax Use in Myeloma
Venetoclax in myeloma: t(11;14) and what else? {Commentary} [Apr 2, 2026] Catherine Pellat-Deceunynck @BloodPortfolio https://t.co/Zar26htoUT #mmsm #PrecisionMedicine https://t.co/zm0Fv6GY2l
New Trial Compares Dara‑Bor‑Dex vs Cy‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/18HJ5kRuNj
Phase
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
Knight Cancer Institute Secures Record $2 Billion Gift
OHSU Knight Cancer Institute receives record $2 billion commitment from Phil and Penny Knight https://t.co/5rgDVaDUtv
Genomic Drivers of Venetoclax Resistance in T(11;14) Myeloma
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) [Apr 2, 2026] @MKaddouraMD et al. @lbaughn @BloodPortfolio https://t.co/qmI6giPG6K #mmsm #PrecisionMedicine https://t.co/hpwUcavTg9
Molecular Profiling Reveals Distinct Signatures in Biphasic FDC Sarcoma
Molecular Characterization of Biphasic Follicular Dendritic Cell Sarcoma [Apr 7, 2026] Hassan et al. Applied Immunohistochemistry & Molecular Morphology https://t.co/WFoJRnwhOk #oncopath
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/fFVUqNssyX
Phase 3 Trial Tests Daratumumab
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/ClwxVAhSy0
Key Needs of Ovarian Cancer Survivors Highlighted
The Needs of Women Treated for Ovarian Cancer: Results From a #gyncsm Twitter Chat [Apr 26, 2018] @TLHagan et al. @JPCRR https://t.co/dOHPGvQ9Zy
COVID-19 Outcomes Worse for Gynecologic Cancer Patients
COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium [Mar 16, 2026] @AlainaJBrown et al. @COVID19nCCC @JCOOA_ASCO https://t.co/lZU3hFiNSS #gyncsm #CCC19 #COVID19nCancer #COVID19 https://t.co/mG18P0SHk3
Recent Cancer Treatments Linked to Worse COVID-19 Outcomes
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/WN6maEUppn
Navigating Myeloma MRD: When to Stop Treatment
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/Y1ti72KB2p
MRD‑Negative Patients Can Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Backs MRD Testing as Early Myeloma Trial Endpoint
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/ejA8KSoxOL